[Drug treatment of obesity].
Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively. This also seems to be the case for rimonabant (Acomplia), which is expected to receive approval in 2005 or 2006. However, until data on morbidity and mortality are available from RCTs, there is no absolute indication for prescribing drugs for treatment of obesity.
Svendsen
Ole Lander
OL
Astrup H:S Bispebjerg Hospital, Endokrinologisk Sektion, Intern Medicinsk Klinik I, København NV. ols01@bbh.hosp.dk
Toubro
Søren
S
Breum
Leif
L
Bruun
Jens Meldgaard
JM
Astrup
Arne V
AV
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use; D004053:Diethylpropion / Q000009:adverse effects / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D013997:Time Factors; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D004791:Enzyme Inhibitors; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D000077403:Orlistat; D004053:Diethylpropion; D000077285:Rimonabant; C058254:sibutramine